Genomic Curator for Cancer - Remote

$3,000 - $4,000 monthly
Part time Biotech QA-Quality Control Writing Skills

Job Description

PRIORITY RESPONSIBILITY

Provide written interpretations following the AMP guidelines for the evaluation of the clinical significance of biomarkers in cancer for the purpose of NGS-based genetic testing. Golden Helix provides an implementation of the somatic scoring guidelines published by AMP with widely adopted analysis software VarSeq and VSClinical. In this part-time, flexible, remote-friendly position, you will join the team that maintains and builds out Golden Helix CancerKB: a knowledgebase of expert-written interpretations for the most common biomarkers in the most common cancers.

ESSENTIAL DUTIES

Genomic Biomarker Interpreter

  • Generate clear, concise clinical interpretations for cancer biomarkers in the context of Next-Generation Sequencing (NGS)-based targeted molecular therapy clinical tests
  • Identify and classify variants in accordance with Golden Helix’s variant curation process
  • Master the relevant capabilities of Golden Helix’s software
  • Other duties as directed.

QUALIFICATIONS

  • PhD in Oncological Sciences, Molecular Genetics, Human Genetics or similar
  • Experience writing variant interpretations or biomarker interpretations
  • Strong working knowledge of laboratory genetics and genomics (e.g. target capture/amplification and next-generation sequencing).
  • Well organized, self-directed and highly detailed.
  • Strong oral and written communication skills.

MEASUREMENTS

The Genomic Curator for Cancer will be measured on:

  • Quality of interpretations written
  • Efficiency in synthesizing diverse sources of information into clear and comprehensive interpretations.

How to Apply:

If you are interested in a challenging and rewarding position with an exciting company, please send your resume and letter of interest to personnel@goldenhelix.com.

Please share an example of your writing as it pertains to variant interpretation. Ideally, this would be in the context of interpreting somatic mutations in cancer and the clinical evidence around that variant as a biomarker for targeted molecular therapy.